MedPath

Endometrial Genomic Profile in Endometrial Priming

Not Applicable
Completed
Conditions
Genomic Human Endometrial Expression Profile
Registration Number
NCT01778452
Lead Sponsor
Instituto Valenciano de Infertilidad, IVI VALENCIA
Brief Summary

The aim of this study is to analyse genomics profile expression in endometrium under different endometrial priming for recipients.

Detailed Description

We analyze the genomic profile of egg donors in different endometrial priming protocols, compared with natural cycle, including the conventional single long acting GnRH agonist injection in the mid luteal phase of the previous cycle of the endometrial priming and the single daily antagonist injection (Cetrorelix 0.25 mg) administered in the early follicular phase followed by endometrial priming. Endometrial biopsy will be taken in luteinizing hormone

* 7 or with P4 +5 in cases with endometrial priming with oestrogens therapy.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
6
Inclusion Criteria
  • 6 egg healthy volunteer egg donors.
  • Volunteers.
  • 18-35 years old
  • Healthy.
  • BMI <28.
Exclusion Criteria
    • BMI > 28
  • Smokers-

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
genetic endometrial human profile expressionOocyte donors will be followed up for four to six months

implantation related genes profile expression

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ivi Valencia

🇪🇸

Valencia, Spain

Ivi Valencia
🇪🇸Valencia, Spain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.